A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Intervention/treatment:
PF-07872412 (25-VALENT PNEUMOCOCCAL CONJUGATE (25VPNC) VACCINE)
Medical condition:
PNEUMOCOCCAL DISEASE
Protocol code:
C4931007
Control number:
306005
Status:
Recruiting
Approved:
May 22, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07573462
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
42 Days to 98 Days
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Pfizer CT.gov Call Center
Role
CONTACT
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA ULC

Locations

Ontario

Bluewater Clinical Research Group Inc.
Sarnia, Ontario, N7T 4X3
NOT_YET_RECRUITING
Milestone Research Inc.
London, Ontario, N5W 6A2
NOT_YET_RECRUITING
Did you find what you were looking for?